A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

Neuro-Oncology

Volumn 13, Issue 4, 2011, Pages 437-446

  Wen, Patrick Y ^a   Schiff, David ^b   Cloughesy, Timothy F ^c   Raizer, Jeffrey J ^d   Laterra, John ^e   Smitt, Melanie ^f   Wolf, Michael ^f   Oliner, Kelly S ^f   Anderson, Abraham ^f   Zhu, Min ^f   Loh, Elwyn ^f   Reardon, David A ^g  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f AMGEN INC   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AMG 102; C Met; Glioblastoma; Hepatocyte growth factor; Phase II clinical trial.; Rilotumumab

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CILENGITIDE; LENALIDOMIDE; RILOTUMUMAB; THALIDOMIDE;

ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; CONFUSION; CONVULSION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; EDEMA; FATIGUE; FEMALE; GENITAL EDEMA; GLIOBLASTOMA; GLIOSARCOMA; HEADACHE; HUMAN; HYPOCALCEMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-MET; SURVIVAL RATE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79955766450     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq198     Document Type: Article

References (40)

1. Wen PY, Kesah S. Malignant gliomas in adults. N Engl J Med 2008;359(5):492-507.
2. Radhakrishnan K, Mokri B, Parisi JE, O'Fallon WM, Sunku J, Kurland LT. The trends in incidence of primary brain tumors in the population of Rochester, Minnesota. Ann Neurol. 1995;37(1):67-73.
3. Kozak KR, Mahadevan A, Moody JS. Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol. 2009;11(2):183-191
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996. (Pubitemid 40349501)
5. Chi AS, Sorensen AG, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist. 2009;14(6) 621-636.
6. Wen PY, Brandes AA. Treatment of recurrent high-grade gliomas. Curr Opin Neurol. 2009;22(6):675-664.
7. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740-745.
8. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
9. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997;57(23):5391-5398. (Pubitemid 27516379)
10. Abounader R, Lai B, Luddy C, et al. In vivo targeting of SF/HGF and c-Met expression via UlsnRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 2002;16(1):108-110.
11. Moriyama T, Kataoka H, Seguchi K, Tsubouchi H, Koono M. Effects of hepatocyte growth factor (HGF) on human glioma cells in vitro: HGF acts as a motility factor in glioma cells. Int J Cancer. 1996;66(5):678-685. (Pubitemid 26199172)
12. Bowers DC, Fan S, Walter KA, et al. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res. 2000;60(15):4277-4283. (Pubitemid 30636617)
13. Arrieta O, Garcia E, Guevara P, et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer. 2002;94(12):3210-3218. (Pubitemid 34670504)
14. Kong DS, Song SY, Kim DH, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009;115(1):140-148.
15. Garcia-Navarrete R, Garcia E, Arrieta O, Sotelo J. Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. J Neurooncol. 2010;97(3):347-351
16. Cao B, Su Y, Oskarsson M, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci USA. 2001;98(13): 7443-7448. (Pubitemid 32567968)
17. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12(20 Pt 1):6144-6152. (Pubitemid 44703780)
18. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 2006;66(3):1721-1729. (Pubitemid 43259957)
19. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts Clin Cancer Res. 2007;13(22 Pt 1):6735-6742. (Pubitemid 350206811)
20. Lai B, Goodwin CR, Sang Y, et al. EGFRvlll and c-Met pathway inhibitors synergize against PTEN-null/EGFRvlll + glioblastoma xenografts. Mol Cancer Ther. 2009;8(7):1751-1760.
21. Kim KJ, Wang L, Su YC, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res. 2006;12(4):1292-1298. (Pubitemid 43342521)
22. Gordon MS, Sweeney CJ, Mendelson DS, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res. 2010;16(2):699-710.
23. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280. (Pubitemid 20195640)
24. Yoshimoto K, Dang J, Zhu S, et al. Development of a real-time RT-PCR assay for detecting EGFRvlll in glioblastoma samples. Clin Cancer Res. 2008;14(2):488-493. (Pubitemid 351226117)
25. Clopper CJ, Pearson ES. The use of confidence or fiducial limits Illustrated in the case of the binomial. Biometrika. 1934;26(4) 404-413.
26. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007;82(1):81-83.
27. Quant EC, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 2009;11(5):550-555.
28. Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol. 2010;12(6):603-607.
29. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ Clinical features, mechanisms, and management of pseudo-progression in malignantgliomas. Lancet Oncol. 2008;9(5) 453-461 (Pubitemid 351597795)
30. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007;318(5848):287-290. (Pubitemid 47574858)
31. Lai B, Xia S, Abounader R, Laterra J. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin Cancer Res. 2005;11(12):4479-4486. (Pubitemid 40825638)
32. Wen PY, M. Prados M, Schiff D, et al. Phase 2 study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2 and RET in patients with progressive glioblastoma. J Clin Oncol. 2010;28:153
33. Rosen PJ, Sweeney CJ, Park DJ, et al. A phase lb study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res. 2010;16(9):2677-2687.
34. Yap TA, Harris D, Barriuso J, et al. Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a-day schedule [abstract]. J Clin Oncol. 2008;26:3584.
35. Eder IP, Shapiro Gl, Appleman U, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res. 2010;16(13):3507-3516.
36. Ramanathan RK, Payumo FC, Papadopoulos KP, et al. A phase 1, first in human, study of SCH 900105, an antihepatocyte growth factor (HGF) monoclonal antibody, in subjects with advanced solid tumors [abstract] Mol Cancer Ther. 2009;8:A100.
37. Brown PD, Krishnan S, Sarkaria JN, et al. Phase l/ll trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol. 2008;26(34):5603-5609.
38. Viana-Pereira M, Lopes JM, Little S, et al. Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvlll mutation in Portuguese high-grade gliomas. Anticancer Res. 2008;28(2A):913-920. (Pubitemid 351578937)
39. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvlll in glioblastoma multiforme patients. Clin Cancer Res. 2005;11(4):1462-1466. (Pubitemid 40315227)
40. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase I trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27(8):1268-1274.